Thompson Peter A. sold 101 shares of Sionna Therapeutics, Inc. at $44.49 for −$4.49k on May 27, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Director
DIR
Filed May 29, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$4,493.49Shares × reported price
Shares traded
101Common Stock
Price per share
$44.49Reported price. Read footnotes for ranges.
% of reported position traded
<0.01%This security and ownership context
Holdings after
2,671,721Indirect · See footnotes
Trade date
May 27, 2026Sell
Filed
May 29, 2026, 9:02 PM ET3-day reporting delay
Accession
0000947871-26-000588Code S · Transaction 96526
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 2,671,822 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

SION price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SION · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −8.4%1w ago −7.8%1d ago +0.1%
Returns since7d −17%30d +0.4%90d180d1y

Footnotes in full

F1: These securities were sold pursuant to a 10b5-1 plan. F2: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. The Reporting Person is a member of OrbiMed Advisors. F3: Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.